According to our study on stimulated IFN production as well as in other studies (14, 21), type I IFN plays a major role in the activation of type II IFN and represents a strategic target for early treatment of COVID-19 patients, in order to destroy the immune evasion caused by SARS-CoV-2 and to treat the specific immune dysfunction. This evidence concerns the gene IFNA1 and immune system disorder.